Highest-materiality recent filing
Aspire Biopharma files 1-for-30 reverse stock split
Filed 1-for-30 reverse stock split of common stock on May 11, 2026.
Aspire Biopharma closes $21M private placement, secures $22.5M credit facility for DCS acquisition
Closed second tranche of $10M (12,500 preferred shares); total gross proceeds $21M from private placement.
Purchase price of $30M cash for 100% of DCS; DCS generated >$200M revenue and >$22M adjusted EBITDA in FY2025 (unaudited).
Aspire Biopharma shareholders approve reverse stock split and authorized share increase
Reverse stock split ratio range 1:5 to 1:500 approved: 2,096,356 for, 582,185 against, 12,852 abstain.
Aspire Biopharma closes $10M second tranche of Series A preferred offering; amends certificate
Second closing issued 12,500 Series A Convertible Preferred Shares for gross proceeds of $10,000,000.
Aspire Biopharma signs LOI to acquire Driver Controls Systems unit for $30M
Entered non-binding LOI to acquire Driver Controls Systems business unit of Firefish Topco for $30M cash-free, debt-free.
Aspire Biopharma raises up to $21M via convertible preferred stock; board adds Balatsos
Initial closing of 13,750 Series A Convertible Preferred Shares for $11M gross proceeds; up to $21M total available.
Filed Certificate of Designation for 25,000 shares of Series A Convertible Preferred Stock on Feb 2, 2026.
Aspire Biopharma converts ~$1.75M debt from PowerUp sponsors into common stock
Exchanged ~$1.75M debt for common stock at closing price less $0.01/share; holders can submit up to 4 exchange notices by Jan 31, 2026.
Aspire Biopharma enters $100M ELOC with Arena, terminates prior ELOC
Entered into $100M equity line of credit (ELOC) with Arena Business Solutions, effective Nov 11, 2025.
Aspire Biopharma holders approve reverse split (1:5-1:40) and 19.99%+ note issuance
Reverse stock split proposal passed: 24,965,481 for, 5,988,513 against, 29,704 abstain.
Nasdaq notifies Aspire Biopharma of delisting for MVLS and bid price non-compliance; company appeals
On Oct 15, 2025, Nasdaq Staff notified the Company of delisting due to failure to comply with the MVLS Rule ($50M minimum) and Bid Price Rule ($1.00 minimum).
Aspire Biopharma dismisses auditor Bush, appoints Turner Stone; gets $1M funding tranche
Dismissed Bush & Associates CPA as independent auditor effective Sept 22, 2025; 2024 audit included going concern explanatory paragraph.
Aspire Biopharma raises $7.75M via convertible notes with 20% OID, maturity Feb 2026
Aggregate principal $9.6875M issued at $7.75M subscription price (20% OID) for three tranches.
CEO and two directors resign; interim CEO appointed; director cites irreconcilable differences
Michael Howe steps down as CEO and Director effective July 24, 2025; no disagreement with company.
Aspire Biopharma CEO Kraig Higginson Steps Down, Michael C. Howe Appointed as New CEO
Kraig Higginson resigned as CEO effective June 10, 2025, and will serve as Executive Chairman.
the Board of Directors appointed Michael Howe, currently a member of the Board of Directors, to serve as Chief Executive Officer of the Company, effective June 10, 2025.
On June 10, 2025, Kraig Higginson, Chief Executive Officer of Aspire Biopharma Holdings, Inc. (the “Company”), notified the Board of Directors of his intention to step down from the role of Chief Executive Officer, effective June 10, 2025.
Max materiality 0.90 · Median 0.65 · Most common event other_material